AnalystsInsight

Kevin DeGeeter (Ladenburg Thalmann & Co.): Analyst Track Record and Price‑Target Accuracy

How often Kevin DeGeeter’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 576 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Kevin DeGeeter ranks #674 of 1,000 analysts in Exent’s scoring (4.7★).
  • 45.4% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 113 days; 34.2% of calls were up 12 months later.
  • Most‑covered stocks: ORIC, FLGT, BNGO, OTC-NTBLQ.
  • Free on Exent: Kevin DeGeeter’s full record, with ratings 3 days after publication.

Kevin DeGeeter’s track record at a glance

Kevin DeGeeter of Ladenburg Thalmann & Co. ranks #674 of the 1,000 analysts Exent scores, with a 4.7★ rating and a focus on healthcare. Over a 7‑year lookback, 45.4% of Kevin’s price targets were reached, 7.0 points below the 52.4% average across all analysts.

MetricKevin DeGeeterAll analysts
Price‑target hit rate45.4%52.4%
Median days to hit target113 days91 days
Calls up after 12 months34.2%64.0%
Median 12‑month return of calls−30.0%+13.4%
Hit rate, last 2 years0.0%—
Average worst drop after a call−42.3%—
Ratings in the sample576—
Stocks covered36—

The full records of Exent’s top 90 analysts and the top 50 of each sector, and the stocks where several of them agree right now, are members‑only in Exent Gems.

How fast price targets were reached

Time to reach the targetKevin DeGeeter
Under 30 days18.2%
30–90 days22.1%
90–180 days33.8%
Over 180 days26.0%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Kevin DeGeeter covers most

StockRatings in the sample
ORIC29
FLGT27
BNGO26
OTC-NTBLQ26
CLRB21
TSHA21
PSNL20
MDWD20

In the past year Kevin’s ratings were 95% Buy, 5% Hold and 0% Sell.

Kevin DeGeeter’s latest ratings

DateStockActionRatingPrice target
Aug 14, 2026CLRBReiterated: BuyBuy$10.00
Jun 18, 2026ELTXInitiated Coverage: BuyBuy$12.00
Jun 15, 2026TRAWDowngraded: HoldHold$0.00
May 15, 2026CLRBInitiated Coverage: BuyBuy$10.00
May 15, 2026CLRBInitiated CoverageBuy$10.00
May 11, 2026URGNInitiated Coverage: BuyBuy$43.00
May 11, 2026URGNInitiated CoverageBuy$43.00
Apr 15, 2026ELTXInitiated Coverage: BuyBuy$20.00
Jan 30, 2026TRAWInitiated CoverageBuy$6.50
Jan 30, 2026TRAWInitiated Coverage: BuyBuy$6.50
Jan 23, 2026DCOYInitiated Coverage: BuyBuy$2.50
Jan 23, 2026DCOYInitiated CoverageBuy$2.50
  • Aug 14, 2026
    Stock
    CLRB
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $10.00
  • Jun 18, 2026
    Stock
    ELTX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $12.00
  • Jun 15, 2026
    Stock
    TRAW
    Action
    Downgraded: Hold
    Rating
    Hold
    Price target
    $0.00
  • May 15, 2026
    Stock
    CLRB
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $10.00
  • May 15, 2026
    Stock
    CLRB
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $10.00
  • May 11, 2026
    Stock
    URGN
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $43.00
  • May 11, 2026
    Stock
    URGN
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $43.00
  • Apr 15, 2026
    Stock
    ELTX
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $20.00
  • Jan 30, 2026
    Stock
    TRAW
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $6.50
  • Jan 30, 2026
    Stock
    TRAW
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $6.50
  • Jan 23, 2026
    Stock
    DCOY
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $2.50
  • Jan 23, 2026
    Stock
    DCOY
    Action
    Initiated Coverage
    Rating
    Buy
    Price target
    $2.50

Kevin’s ratings are free on Exent 3 days after publication. Exent Gems has them the same day, with the calls of the top‑ranked analysts and the stocks where several of them agree.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 20, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Gems shows Kevin DeGeeter’s live ratings and those of the top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Kevin DeGeeter ranks #674 of 1,000 with a 4.7★ rating. 45.4% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 34.2% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Kevin DeGeeter’s success rate is 38.1% by the ranking source and 45.4% by Exent’s price-target hit-rate backtest, with a median of 113 days to reach a target.

Kevin DeGeeter (Ladenburg Thalmann & Co.) covers 36 stocks, mostly in healthcare. The most frequently rated are ORIC, FLGT, BNGO, OTC-NTBLQ, CLRB.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.